{"name":"Journey Medical Corporation","slug":"journey-medical-corporation","ticker":"","exchange":"","domain":"journeymedicalcorporation.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Dose 2 of glycopyrronium, 3.75% QD","genericName":"Dose 2 of glycopyrronium, 3.75% QD","slug":"dose-2-of-glycopyrronium-3-75-qd","indication":"Other","status":"phase_2"},{"name":"glycopyrronium Topical Wipes","genericName":"glycopyrronium Topical Wipes","slug":"glycopyrronium-topical-wipes","indication":"Primary hyperhidrosis (excessive sweating)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DFD-29","genericName":"DFD-29","slug":"dfd-29","indication":"Bacterial skin infections (Phase 3)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dose 1 of glycopyrronium, 2.5% QD","genericName":"Dose 1 of glycopyrronium, 2.5% QD","slug":"dose-1-of-glycopyrronium-2-5-qd","indication":"Treatment of glaucoma","status":"phase_2"}]}],"pipeline":[{"name":"Dose 2 of glycopyrronium, 3.75% QD","genericName":"Dose 2 of glycopyrronium, 3.75% QD","slug":"dose-2-of-glycopyrronium-3-75-qd","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DFD-29","genericName":"DFD-29","slug":"dfd-29","phase":"phase_3","mechanism":"DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function.","indications":["Bacterial skin infections (Phase 3)"],"catalyst":""},{"name":"Dose 1 of glycopyrronium, 2.5% QD","genericName":"Dose 1 of glycopyrronium, 2.5% QD","slug":"dose-1-of-glycopyrronium-2-5-qd","phase":"phase_2","mechanism":"Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating.","indications":["Treatment of glaucoma"],"catalyst":""},{"name":"glycopyrronium Topical Wipes","genericName":"glycopyrronium Topical Wipes","slug":"glycopyrronium-topical-wipes","phase":"phase_3","mechanism":"Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion.","indications":["Primary hyperhidrosis (excessive sweating)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPNHdueEx2aUxqUEhqTUQzWGtzS1ZFS0NYUDNSeXUteXJPUGF3ZlFSeXR0cVM5bUhtRVFfS3hkWGlteFNlempzM1pITTBXcFpwajdBMzQ0Y2w3RXJnNXpRdkFtQWxldDh4SlR1cUxsM21POG5KdmdZRnRULXdydm5TcGthX1ZxalFmZlFVVVdBcEJqcHNsUzJzV3k5V3ZkN2tsXzZlT3RLbEF5VjVMV0p2eVhrM3FBZDFLd3M3Tk9TcmxObXljUEJDMG5qNGRmeDFYVmE3MXVUWUtUb280SWNmLU4wNXhqLXJsTTNYY1JIS01IcUxVTkIwT2pfdVNfQ0h6OS1xVXVCUVpscEQzclBB?oc=5","date":"2026-03-26","type":"regulatory","source":"Minichart","summary":"Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - Minichart","headline":"Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intel","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNQlo2eUFCbTRCRUxPWjJQSjc3NkMyMUZhQzIwZ3Z6MFNqdmhteGVmLWpzeC12Mjl5S3Q4UkxsT0tuSWc0T0FEVHhxWXRsUGdkSjNGSEJHN1hyYVR4NjVobGlUUnJkUWhibVYtdml2NFFyb3ZyQUJrTXUzNjAxWW5hUGNmWUJxejF4anNDeWlCRFFsbEE4SEJEOGZNVXVldjJHYkNEcFJ4dURZTk9Id3B4b2ZrZ2syc2xwbEdkVkpjZTN4QlJQcXQ1ODZ3UjRkNkRCdnc0NlFORjN5dWV6S1FQeE4zQ3hMMHV1MU1NVTAtRXdNbjdIRmtxTm9jdmFQTVJnRkE?oc=5","date":"2026-03-25","type":"pipeline","source":"GlobeNewswire","summary":"Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire","headline":"Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQUkc1VUZ2UC1KajVMalJGamxzdDRBSHNhOUFicnFhb0xjLVFCYmdqck1xVlA2ci1Pd3ZMWHhXNk9wcGUyampWbk43aXgySmhGTk5kMG40VzFfbVZjMGtjY2k5ZTNsSHJTSkpBUzI0dVE1UFEtc3ZfUDdIcVVwc05adEZfcGtRWDRHaDlxZ0tJOUtWbjVKTmtfb1hPOV9NY0hBVS1tOWxzOHMwdW9RV1pHU2FGNFJYTjBiRlRJX0dB?oc=5","date":"2026-03-25","type":"earnings","source":"AD HOC NEWS","summary":"Journey Medical Corp stock faces key test ahead of Q4 2025 earnings release on March 25, 2026 - AD HOC NEWS","headline":"Journey Medical Corp stock faces key test ahead of Q4 2025 earnings release on March 25, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQUXZreDRieE1Xb3h4bERkc3VzWlNDZ1V6SW01dGhxRFZUTDJjdHdELVFMWHFOZ3BNYU9QLURqLWRUcVU3czhGRHQ1em95V3AwN1k0Y1lIMTItNHJGdWhHNGxhdmpldEg0ck1BTDlIN25qUUhNWGpNQnFkTF9kelpUS2gxMXVkMEJwQXRzNEVBdGxIX3JxSlpYZlFETTRySTdqZnJkZ3ItbnhSZEdkcmV4Q29nSENuYWxlblE?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25 - Stock Titan","headline":"Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNanRKN3NWeVRucFd5bWk4TjlPTWEwUXd3ejNDX0U5OXJKN3J1Tmw0UHNGS1JQMVgtQ2RLbWdRZGl3bGRfM1VpQkpuSUhSLWNHdXpXVnhySzlHZGtlVEtXbTdWLWluMlN6aHVrcThHeWFhR3FJVE56T0lfZUZkTkJkRlJqSkhNUlhzVVpvZUNpX0Zsck1OTHZQTFBtSmZKVmR0Ri1DckNQaEdybnZoOGx5Ynh4X0pZUUhpWlN1Zzc3cVZvaUxtd215NDJyWVA4X0tLQTB1LW9YeE5fTlRZcGVxeWNDQWdpNUVBQjRmUVVCeVFxQQ?oc=5","date":"2026-03-18","type":"pipeline","source":"GlobeNewswire","summary":"Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire","headline":"Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBWY2lNeUdKRGxsa1RaVVlXN3hJcUgyY0tCRWZ0WnZQcTNtWHJoMlZaaUJmdnE3eVFQZWhxN3pKcXBHd1pmR21zV0V0R3ZqRU9YN3lPWHo3dkJfanowTGtwV1lzQUhGUQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"DERM SEC Filings - Journey Medical Corp 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"DERM SEC Filings - Journey Medical Corp 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBfYVdLNlgyZmwyV2o5bjltTVhQNXFBWGNzQWRpNlpERElVUlBkTWlSVmsxNmpOdEl5bmlWSFpUYlBSbFl4LTAxNW9hLXJkbElnY0ZqemFMdEdDMEdWQUdwQlJWSWp0b0JqX1RhZ1dYWkNOeHRlbkE?oc=5","date":"2026-01-30","type":"pipeline","source":"Fortune Business Insights","summary":"Rosacea Drugs Market Size, Share, Trends | Growth [2026-2034] - Fortune Business Insights","headline":"Rosacea Drugs Market Size, Share, Trends | Growth [2026-2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPNkFRUjZ4MEU3bnFmUjhkVGw3bWpBMVNGdklLMmMzcnk3OVNucmxHNF83Sm1HWTJqUmNHdnRqS2FLdTViOUFSVjFtOGtZOTQxQmRRSWsxXzdoRzNxczV5NUJvSlJZTmE0LTF5N3puNU02WFRoRnhZVmdPN0t4NXpqX0pFX1ZNZTF5RnhfMQ?oc=5","date":"2025-11-19","type":"pipeline","source":"Yahoo Finance","summary":"What Makes Journey Medical Corporation (DERM) a Good Investment? - Yahoo Finance","headline":"What Makes Journey Medical Corporation (DERM) a Good Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNEgtb0R3dlAteVJPZUFDX2lpRmdLOEJXd2tGMHF1ZXAxMWNoS29XaXVOUlVCM0JhVVR1a0h2cnExaHlTS3VkZngxMUhYNXZldEYtZkozMGJVcEwxek05U3M3ZHZYajdYRFNMYWlOMXZoSi1kSkZKM19jSVE1S3N2ZG1salp4TzZxaFpXaEhibkJtOV9CTVBFRThFRlFCUGNvZWF3VnhHYXp3YldyMFk4QjZxVWFCV3ZNX3pzQ041aUtkNWtjejNGejRJU2xCOHBiQllncHl2cVA5U3Q3Z1E?oc=5","date":"2025-11-12","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Journey Medical’s Q3 2025 shows revenue jump and strategic growth - Investing.com","headline":"Earnings call transcript: Journey Medical’s Q3 2025 shows revenue jump and strategic growth","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-28","type":"pipeline","source":"simplywall.st","summary":"Insiders Who Sold US$887k Of Journey Medical Made The Right Call - simplywall.st","headline":"Insiders Who Sold US$887k Of Journey Medical Made The Right Call","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPSEd3cTBYWVhlMlFadWlta3dYRWpfcGhSbkl6ek05b0U3Ry0xMUtZdC1SaVdyNXJlYTh2R2xyX3V1YlJ4Mkp1anV1M2tVY1dEdzR1cWwtV1BvZXV0LTdMLU5iZjJwcUpEWUk0V2JRdm1KUjFzZU1zRVkxczdmVl9od1h3amhnSzZhaDFYbWp1YnhEUlZWS3VTVTVpM2NFTnlORzBQU2Z3?oc=5","date":"2025-09-06","type":"earnings","source":"Seeking Alpha","summary":"Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon (NASDAQ:DERM) - Seeking Alpha","headline":"Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon (NASDAQ:DERM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-15","type":"pipeline","source":"simplywall.st","summary":"US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results - simplywall.st","headline":"US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":2,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}